Attovia Therapeutics, Inc. Sample Contracts
ATTOVIA THERAPEUTICS, INC.Employment Agreement • July 29th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances)
This letter agreement (“Agreement”) amends and restates the offer letter between you and Attovia Therapeutics, Inc. (the “Company”), dated on or about June 2, 2023 (the “Prior Agreement”) and sets forth the terms of your continued employment with the Company or a subsidiary of the Company. This Agreement is effective as of the closing of the sale of shares of the Company’s common stock to the public pursuant to a registration statement declared effective by the U.S. Securities and Exchange Commission. The terms of your continued employment and the benefits currently provided by the Company are as set forth in this Agreement.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 14th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 31, 2025, by and among Attovia Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”.
LEASE AGREEMENT between BRITTAN WEST OWNER, LLC, a Delaware limited liability company, as “Landlord” and ATTOVIA THERAPEUTICS, INC., a Delaware corporation, as “Tenant”Lease Agreement • July 14th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
The Basic Lease Information set forth above is part of the Lease. In the event of any conflict between any provision in the Basic Lease Information and the Lease, the Lease shall control.
SECOND AMENDED AND RESTATED PLATFORM LICENSE AGREEMENTPlatform License Agreement • July 14th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Second Amended and Restated Platform License Agreement (“Agreement”) is entered into by Alamar Biosciences, Inc. (“Alamar”), having its principal place of business at 47071 Bayside Parkway, Fremont, CA 94538, and Attovia Therapeutics, Inc. (“Licensee”), having its principal place of business at 1091 Industrial Road, Suite 301, San Carlos, CA 94070, and is retroactively effective June 1, 2023 (“Effective Date”). In consideration of the mutual covenants and promises set forth in this Agreement, the parties agree as follows:
FORM OF INDEMNITY AGREEMENTIndemnification Agreement • July 14th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnity Agreement, dated as of _____________, 2026 is made by and between Attovia Therapeutics, Inc., a Delaware corporation (the “Company”), and _____________________, a director, officer or key employee of the Company or one of the Company’s Subsidiaries or Affiliates (as those terms are defined below) or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
•] Shares ATTOVIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • July 29th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ATTOVIA THERAPEUTICS, INC. FORM OF STOCK PURCHASE AGREEMENTStock Purchase Agreement • July 14th, 2026 • Attovia Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of [●], (the “Effective Date”), by and between ATTOVIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), [●] (“Purchaser”)[, and [●] (the “Service Provider”)].